表紙:変形性関節症治療薬の世界市場 (~2025年):部位 (膝・手)・薬剤タイプ (NSAID・鎮痛薬・コルチコステロイド)・投与経路 (非経口)・流通経路 (院内薬局)・販売区分 (処方薬)・地域別
市場調査レポート
商品コード
977389

変形性関節症治療薬の世界市場 (~2025年):部位 (膝・手)・薬剤タイプ (NSAID・鎮痛薬・コルチコステロイド)・投与経路 (非経口)・流通経路 (院内薬局)・販売区分 (処方薬)・地域別

Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs)-Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 193 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
変形性関節症治療薬の世界市場 (~2025年):部位 (膝・手)・薬剤タイプ (NSAID・鎮痛薬・コルチコステロイド)・投与経路 (非経口)・流通経路 (院内薬局)・販売区分 (処方薬)・地域別
出版日: 2020年12月14日
発行: MarketsandMarkets
ページ情報: 英文 193 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の変形性関節症治療薬の市場規模は予測期間中8.7%のCAGRで推移し、2020年の73億米ドルから、2025年には110億米ドルの規模に成長すると予測されています。鎮痛剤の大幅な利用の拡大、変形性関節症の有病率の拡大、変形性関節症にかかりやすい人口層の増加、スポーツ傷害の増加、個別化医療が好まれる傾向、製品開発のための提携などの要因が同市場の成長を推進する見通しです。

薬剤タイプ別で見ると、関節内補充薬の部門が2020年に最大のシェアを示す見通しです。また、投与経路別では、非経口経路の部門が同年、最大のシェアを占め、予測期間中は最大のCAGRを示すと予測されています。投与が容易であり、薬物動態および薬力学が優れているため、同部門の成長が牽引されています。

当レポートでは、世界の変形性関節症治療薬の市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、関連法規制、疫学的データ、市場規模の推移・予測、部位・薬剤タイプ・投与経路・流通経路・販売区分・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • COVID-19の影響分析
  • 平均販売価格
  • 規制シナリオ
  • 疫学

第6章 市場分析・予測:部位別

  • 変形性膝関節症
  • 変形性股関節症
  • 手変形性関節症
  • 変形性小関節関節症

第7章 市場分析・予測:薬剤タイプ別

  • 関節内補充薬
  • 非ステロイド性抗炎症薬
  • 鎮痛薬
  • コルチコステロイド

第8章 市場分析・予測:投与経路別

  • 非経口
  • 経口
  • 局所

第9章 市場分析・予測:流通経路別

  • 院内薬局
  • 小売薬局
  • オンライン薬局

第10章 市場分析・予測:販売区分別

  • 処方薬
  • OTC薬

第11章 市場分析・予測:地域・主要国別

  • 欧州
    • イタリア
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • その他
  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • その他
  • その他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第12章 競合情勢・企業プロファイル

  • 競合情勢
  • 企業プロファイル
    • PFIZER, INC.
    • HORIZON THERAPEUTICS PLC
    • SANOFI
    • JOHNSON & JOHNSON
    • BAYER AG
    • ABBOTT
    • GLAXOSMITHKLINE PLC
    • ZIMMER BIOMET HOLDINGS
    • NOVARTIS AG
    • FLEXION THERAPEUTICS, INC.
    • ANIKA THERAPEUTICS
    • ELI LILLY
    • HANMI PHARM. CO., LTD.
    • ASSERTIO THERAPEUTICS, INC.
    • LABORATORIO REIG JOFRE
    • KITOV PHARMACEUTICALS
    • VIRCHOW BIOTECH
    • FERRING PHARMACEUTICALS
    • BIOVENTUS
    • ALMATICA PHARMA LLC
    • ATNAHS
    • PHARMED LIMITED
    • ORTHOGENRX
    • LABRHA
    • FIDIA FARMACEUTICI S.P.A.

第13章 付録

目次
Product Code: PH 7393

The global osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The growth of this market is driven significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number of sports injuries. Also, the preference for personalized medicines for osteoarthritis, coupled with collaborations for product development to offer an opportunity for the growth of the market during the forecast period.

"Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020."

Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis.

"Viscosupplementation agents is expected to hold the largest share of the osteoarthritis therapeutics market, in 2020."

Based on drug type, the market is classified as, viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is subsegmented into duloxetine and acetaminophen, while the NSAIDs segment is subsegmented into naproxen, aspirin, diclofenac, ibuprofen, and other NSAIDs. The viscosupplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2019. The rising incidence of knee osteoarthritis is the major factor driving the growth of this segment. Viscosupplementation effectively eases the pain of osteoarthritis through injections that fill up the joint's synovial fluid, thus offering better lubrication of the joints.

"Parental route is expected to hold the largest share of the osteoarthritis therapeutics market in 2020."

On the basis of route of administration, the osteoarthritis therapeutics market has been segmented into oral, topical, and parenteral routes. The parenteral route accounted for the largest share of this market in 2019 and is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the wide adoption of the parenteral route for administering osteoarthritis therapeutics owing to the ease of administration and the better pharmacokinetics and pharmacodynamics, resulting in better patient compliance.

"Hospital pharmacies segment commanded the largest share of the osteoarthritis therapeutics market in 2020."

Based on the distribution channel, the osteoarthritis therapeutics market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. In 2019, hospital pharmacies accounted for the largest share of this market because of the high volume of patients visiting hospitals for osteoarthritis treatments and the wide range of osteoarthritis therapeutics available in these pharmacies. Reimbursements can also be claimed easily on hospital pharmacy purchases, which is another important draw.

"Prescription drugs segment commanded the largest share of the osteoarthritis therapeutics market in 2020."

Based on the purchasing pattern, the osteoarthritis therapeutics market is segmented into OTC and prescription drugs. In 2019, the prescription drugs segment accounted for a larger share of this market as most osteoarthritis therapeutics (viscosupplementation agents and corticosteroids) are only available on prescription.

"Europe commanded the largest share of the osteoarthritis therapeutics market in 2020."

On the basis of region, the osteoarthritis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, Europe commanded the largest share of the osteoarthritis therapeutics market. The large share of this market segment can be attributed to the rising incidence of osteoarthritis, rising geriatric population, and increasing obesity rates in several European countries, coupled with the rising number of injuries due to sports and road accidents.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (20%) , Tier 2 (45%), and Tier 3 (35%)
  • By Designation: C-level (30%), Director-level (20%), and Others (50%)
  • By Region: North America (35%), Europe (24%), AsiaPacific (25%), Middle East and Africa (5%) and Latin America (11%)

The some of the major players operating in this market are Sanofi AG (France), Horizon Therapeutics plc (Ireland) and Pfizer, Inc. (US)

List of Companies Profiled in the Report

  • Sanofi (France)
  • Horizon Therapeutics PLC (Ireland)
  • Johnson & Johnson (US)
  • GlaxoSmithKline PLC (UK)
  • Bayer AG (Germany)
  • Abbott (US)
  • Pfizer, Inc. (US)
  • Eli Lilly (US)
  • Anika Therapeutics, Inc. (US)
  • Novartis AG (Switzerland)
  • Ferring Pharmaceuticals (Switzerland)
  • Bioventus (US)
  • Zimmer Biomet Holdings, Inc. (US)
  • Fidia Farmaceutici s.p.a. (Italy)
  • Flexion Therapeutics, Inc. (US)
  • Pharmed Limited (India)
  • Virchow Biotech (India)
  • Kitov Pharmaceuticals Ltd. (Israel)
  • Assertio Therapeutics, Inc. (US)
  • Atnahs (UK)
  • Almatica Pharma LLC (US)
  • OrthogenRx (US)
  • LABRHA (France)
  • Hanmi Pharm. Co., Ltd. (Korea)
  • Laboratorio Reig Jofre (Spain)

Research Coverage

This report studies the osteoarthritis therapeutics market based on anatomy, drug type, route of administration, prescription pattern, distribution channel, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total osteoarthritis therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on osteoarthritis therapeutics offered by the top 25 players in the osteoarthritis therapeutics market. The report analyzes the osteoarthritis therapeutics market by anatomy, drug type, route of administration, prescription pattern, distribution channel, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the osteoarthritis therapeutics market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the osteoarthritis therapeutics market

Frequently asked questions

  • What are the growth opportunities in the osteoarthritis therapeutics market across major regions in the future?
  • Which type of drug is expected to hold the largest share in the osteoarthritis therapeutics market?
  • Which is the most preferred route of administration of osteoarthritis medications?
  • Which region has a well-developed osteoarthritis therapeutics market?
  • What is the impact of COVID-19 on osteoarthritis therapeutics market?

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
  • 1.8 LIMITATIONS OF THE CURRENT EDITION

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 4 OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH
    • 2.2.2 GROWTH FORECAST
    • 2.2.3 TOP-DOWN APPROACH
    • FIGURE 5 OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020 VS. 2025 (USD BILLION)
    • FIGURE 8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020 VS. 2025 (USD BILLION)
    • FIGURE 9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD BILLION)
    • FIGURE 10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020 VS. 2025 (USD BILLION)
    • FIGURE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2020 VS. 2025 (USD BILLION)
    • FIGURE 12 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2020 VS. 2025 (USD BILLION)

4 PREMIUM INSIGHTS

  • 4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW
    • FIGURE 13 INCREASING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
  • 4.2 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY DRUG TYPE (2019)
    • FIGURE 14 VISCOSUPPLEMENTATION AGENTS SEGMENT TO DOMINATE THE EUROPEAN MARKET IN 2020
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET
    • FIGURE 15 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD IN THE OSTEOARTHRITIS THERAPEUTICS MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Significant adoption of pain medications
      • 5.2.1.2 Increasing prevalence of osteoarthritis
      • 5.2.1.3 Growing population susceptible to osteoarthritis
    • FIGURE 17 SHARE OF OBESE ADULTS, BY REGION (2016)
      • 5.2.1.4 Rising number of sports injuries
    • FIGURE 18 INJURIES CAUSED BY SPORTS ACTIVITIES IN THE US (2019)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment
      • 5.2.2.2 Commercialization of alternatives
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Personalized medicines for osteoarthritis
      • 5.2.3.2 Emerging markets
      • 5.2.3.3 Collaborations for product development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Adoption of non-drug pain management therapies
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS: PHARMACEUTICALS INDUSTRY
    • TABLE 1 COSTS INCURRED AND VALUE ADDED ACROSS THE VALUE CHAIN, BY COMPONENT
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 20 DIRECT DISTRIBUTION-THE PREFERRED STRATEGY OF PROMINENT COMPANIES
  • 5.5 ECOSYSTEM ANALYSIS
    • FIGURE 21 ECOSYSTEM ANALYSIS
  • 5.6 COVID-19 IMPACT ANALYSIS ON THE OSTEOARTHRITIS THERAPEUTICS MARKET
  • 5.7 AVERAGE SELLING PRICE TREND
    • TABLE 2 AVERAGE SELLING PRICE OF OSTEOARTHRITIS DRUGS
  • 5.8 REGULATORY SCENARIO
    • TABLE 3 LIST OF REGULATORY AUTHORITIES IN THE PHARMA INDUSTRY
    • 5.8.1 REGULATORY REQUIREMENTS
      • 5.8.1.1 EU regulations
      • 5.8.1.2 US regulations
  • 5.9 EPIDEMIOLOGY (PATIENT POPULATION)
    • 5.9.1 SEVERITY
    • TABLE 4 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY SEVERITY (2019)
    • 5.9.2 ANATOMY
    • TABLE 5 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY ANATOMY (2019)

6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY

  • 6.1 INTRODUCTION
    • TABLE 6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
  • 6.2 KNEE OSTEOARTHRITIS
    • 6.2.1 RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS
    • TABLE 7 KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 6.3 HIP OSTEOARTHRITIS
    • 6.3.1 SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS
    • TABLE 8 HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 6.4 HAND OSTEOARTHRITIS
    • 6.4.1 RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH
    • TABLE 9 HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 6.5 SMALL JOINT OSTEOARTHRITIS
    • 6.5.1 RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE THE PREVALENCE OF ANKLE OSTEOARTHRITIS
    • TABLE 10 SMALL JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)

7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE

  • 7.1 INTRODUCTION
    • TABLE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • 7.2 VISCOSUPPLEMENTATION AGENTS
    • 7.2.1 VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2019
    • TABLE 12 OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2018-2025 (USD MILLION)
  • 7.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
    • 7.3.1 NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE ADVERSE EFFECTS OF CORTICOSTEROIDS
    • TABLE 13 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 14 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2025 (USD MILLION)
      • 7.3.1.1 Ibuprofen
    • TABLE 15 OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION, 2018-2025 (USD MILLION)
      • 7.3.1.2 Aspirin
    • TABLE 16 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION, 2018-2025 (USD MILLION)
      • 7.3.1.3 Diclofenac
    • TABLE 17 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION, 2018-2025 (USD MILLION)
      • 7.3.1.4 Naproxen
    • TABLE 18 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION, 2018-2025 (USD MILLION)
      • 7.3.1.5 Other NSAIDs
    • TABLE 19 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER NSAIDS, BY REGION, 2018-2025 (USD MILLION)
  • 7.4 ANALGESICS
    • 7.4.1 ACETAMINOPHEN HOLDS THE LARGEST SHARE OF THE ANALGESICS MARKET
    • TABLE 20 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 21 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2018-2025 (USD MILLION)
      • 7.4.1.1 Acetaminophen
    • TABLE 22 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN, BY REGION, 2018-2025 (USD MILLION)
      • 7.4.1.2 Duloxetine
    • TABLE 23 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION, 2018-2025 (USD MILLION)
  • 7.5 CORTICOSTEROIDS
    • 7.5.1 EUROPE AND NORTH AMERICA ARE THE LARGEST MARKETS FOR CORTICOSTEROIDS
    • TABLE 24 OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2018-2025 (USD MILLION)

8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1 INTRODUCTION
    • TABLE 25 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
  • 8.2 PARENTERAL ROUTE
    • 8.2.1 DRUGS INEFFECTIVE WHEN ADMINISTERED ORALLY CAN BE DELIVERED VIA PARENTERAL ROUTE
    • TABLE 26 PARENTERAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 8.3 ORAL ROUTE
    • 8.3.1 ORAL ROUTE IS WIDELY PREFERRED BY BOTH CLINICIANS AND PATIENTS
    • TABLE 27 ORAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 8.4 TOPICAL ROUTE
    • 8.4.1 EASE OF USE, PAINLESS AND NON-INVASIVE ADMINISTRATION HAVE SUPPORTED USE OF TOPICAL ROUTE
    • TABLE 28 TOPICAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)

9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 INTRODUCTION
    • TABLE 29 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
  • 9.2 HOSPITAL PHARMACIES
    • 9.2.1 HOSPITAL PHARMACIES ARE THE LARGEST DISTRIBUTION CHANNEL FOR OSTEOARTHRITIS THERAPEUTICS
    • TABLE 30 OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2018-2025 (USD MILLION)
  • 9.3 RETAIL PHARMACIES
    • 9.3.1 GREATER PREFERENCE FOR RETAIL PHARMACIES HAS AFFECTED MARKET SHARE
    • TABLE 31 OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2018-2025 (USD MILLION)
  • 9.4 ONLINE PHARMACIES
    • 9.4.1 ONLINE PHARMACIES TO REGISTER THE HIGHEST GROWTH
    • TABLE 32 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2018-2025 (USD MILLION)

10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN

  • 10.1 INTRODUCTION
    • TABLE 33 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
  • 10.2 PRESCRIPTION DRUGS
    • 10.2.1 PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET
    • TABLE 34 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2018-2025 (USD MILLION)
  • 10.3 OVER-THE-COUNTER DRUGS
    • 10.3.1 EASE OF PURCHASE AND ADMINISTRATION ARE RESULTING IN A RISING DEMAND FOR OTC DRUGS
    • TABLE 35 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2018-2025 (USD MILLION)

11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 36 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 11.2 EUROPE
    • FIGURE 22 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
    • TABLE 37 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 38 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 39 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 40 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 41 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 42 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 43 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 44 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.2.1 ITALY
      • 11.2.1.1 Italy dominates the European market for osteoarthritis therapeutics
    • TABLE 45 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 46 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 47 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 48 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 49 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 50 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 51 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.2.2 GERMANY
      • 11.2.2.1 Road accidents in the country to propel the demand for osteoarthritis therapeutics
    • TABLE 52 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 53 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 54 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 55 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 56 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 57 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 58 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.2.3 SPAIN
      • 11.2.3.1 High prevalence of osteoarthritis to drive the growth of the market
    • TABLE 59 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 60 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 61 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 62 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 63 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 64 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 65 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.2.4 FRANCE
      • 11.2.4.1 Rising geriatric population to accelerate the growth of the market during the forecast period
    • TABLE 66 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 67 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 68 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 69 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 70 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 71 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 72 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.2.5 UK
      • 11.2.5.1 Increasing obesity rate and rising incidence of musculoskeletal diseases drive the market in the UK
    • TABLE 73 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 74 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 75 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 76 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 77 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 78 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 79 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.2.6 REST OF EUROPE
    • TABLE 80 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 81 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 82 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 83 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 84 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 85 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 86 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
  • 11.3 NORTH AMERICA
    • TABLE 87 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 88 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 89 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 90 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 91 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 92 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 93 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 94 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.3.1 US
      • 11.3.1.1 The US holds the largest share in the North American market
    • TABLE 95 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 96 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 97 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 98 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 99 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 100 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 101 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.3.2 CANADA
      • 11.3.2.1 Rising geriatric and obese populations will drive the incidence of osteoarthritis therapeutics
    • TABLE 102 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 103 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 104 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 105 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 106 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 107 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 108 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 23 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
    • TABLE 109 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 113 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 114 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 115 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 116 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.4.1 JAPAN
      • 11.4.1.1 Japan dominates the osteoarthritis therapeutics market in the APAC
    • TABLE 117 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 118 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 119 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 120 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 121 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 122 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 123 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.4.2 CHINA
      • 11.4.2.1 Rising geriatric population to propel the demand for osteoarthritis therapeutics in China
    • TABLE 124 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 125 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 126 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 127 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 128 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 129 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 130 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Rising prevalence of osteoarthritis to accelerate market growth in India
    • TABLE 131 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 132 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 133 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 134 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 135 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 136 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 137 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Initiatives by market players to support the growth of the market
    • TABLE 138 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 139 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 140 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 141 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 142 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 143 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 144 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Prevalence of osteoarthritis to accelerate the growth of the market
    • TABLE 145 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 146 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 147 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 148 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 149 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 150 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 151 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.4.6 REST OF ASIA PACIFIC
    • TABLE 152 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 153 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 154 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 155 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 156 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 157 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 158 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
  • 11.5 REST OF THE WORLD
    • TABLE 159 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 160 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 161 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 162 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 163 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 164 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 165 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 166 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.5.1 LATIN AMERICA
      • 11.5.1.1 Latin America holds a larger share of the RoW market
    • TABLE 167 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 168 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 169 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 170 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 171 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 172 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 173 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)
    • 11.5.2 MIDDLE EAST AND AFRICA
      • 11.5.2.1 Rising obesity rates to propel market growth
    • TABLE 174 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION)
    • TABLE 175 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
    • TABLE 176 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 177 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION)
    • TABLE 178 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
    • TABLE 179 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
    • TABLE 180 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE & COMPANY PROFILES

  • 12.1 COMPETITIVE LANDSCAPE
    • 12.1.1 OVERVIEW
    • FIGURE 24 KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET, JANUARY 2017-NOVEMBER 2020
    • FIGURE 25 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO NOVEMBER 2020
    • 12.1.2 COMPETITIVE SCENARIO
      • 12.1.2.1 Product launches and approvals
    • TABLE 181 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017-NOVEMBER 2020
      • 12.1.2.2 Collaborations and agreements
    • TABLE 182 KEY COLLABORATIONS AND AGREEMENTS, JANUARY 2017-NOVEMBER 2020
      • 12.1.2.3 Expansions
    • TABLE 183 KEY EXPANSIONS, JANUARY 2017-NOVEMBER 2020
      • 12.1.2.4 Mergers and acquisitions
    • TABLE 184 KEY MERGERS AND ACQUISITIONS, JANUARY 2017-NOVEMBER 2020
      • 12.1.2.5 Other developments
    • TABLE 185 OTHER DEVELOPMENTS, JANUARY 2017-NOVEMBER 2020
    • 12.1.3 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019
    • FIGURE 26 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019
    • 12.1.4 COMPANY EVALUATION MATRIX
      • 12.1.4.1 Stars
      • 12.1.4.2 Emerging leaders
      • 12.1.4.3 Pervasive companies
      • 12.1.4.4 Participants
    • FIGURE 27 OSTEOARTHRITIS THERAPEUTICS MARKET (GLOBAL) COMPANY EVALUATION MATRIX, 2019
  • 12.2 COMPANY PROFILES
  • (Business overview, Products offered, Recent Developments, SWOT analysis, MNM view)**
    • 12.2.1 PFIZER, INC.
    • FIGURE 28 PFIZER, INC.: COMPANY SNAPSHOT (2019)
    • 12.2.2 HORIZON THERAPEUTICS PLC
    • FIGURE 29 HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2019)
    • 12.2.3 SANOFI
    • FIGURE 30 SANOFI: COMPANY SNAPSHOT (2019)
    • 12.2.4 JOHNSON & JOHNSON
    • FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
    • 12.2.5 BAYER AG
    • FIGURE 32 BAYER AG: COMPANY SNAPSHOT (2019)
    • 12.2.6 ABBOTT
    • FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2019)
    • 12.2.7 GLAXOSMITHKLINE PLC
    • FIGURE 34 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
    • 12.2.8 ZIMMER BIOMET HOLDINGS
    • FIGURE 35 ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
    • 12.2.9 NOVARTIS AG
    • FIGURE 36 NOVARTIS: COMPANY SNAPSHOT (2019)
    • 12.2.10 FLEXION THERAPEUTICS, INC.
    • FIGURE 37 FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2019)
    • 12.2.11 ANIKA THERAPEUTICS
    • FIGURE 38 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2019)
    • 12.2.12 ELI LILLY
    • FIGURE 39 ELI LILLY: COMPANY SNAPSHOT (2019)
    • 12.2.13 HANMI PHARM. CO., LTD.
    • FIGURE 40 HANMI PHARM.CO., LTD.: COMPANY SNAPSHOT (2019)
    • 12.2.14 ASSERTIO THERAPEUTICS, INC.
    • FIGURE 41 ASSERTIO THERAPEUTICS: COMPANY SNAPSHOT (2019)
    • 12.2.15 LABORATORIO REIG JOFRE
    • FIGURE 42 LABORATORIO REIG JOFRE: COMPANY SNAPSHOT (2019)
    • 12.2.16 KITOV PHARMACEUTICALS
    • FIGURE 43 KITOV PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2019)
    • 12.2.17 VIRCHOW BIOTECH
    • 12.2.18 FERRING PHARMACEUTICALS
    • 12.2.19 BIOVENTUS
    • 12.2.20 ALMATICA PHARMA LLC
    • 12.2.21 ATNAHS
    • 12.2.22 PHARMED LIMITED
    • 12.2.23 ORTHOGENRX
    • 12.2.24 LABRHA
    • 12.2.25 FIDIA FARMACEUTICI S.P.A.
  • *Details on Business overview, Products offered, Recent Developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INDUSTRY INSIGHTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 AVAILABLE CUSTOMIZATIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS